CETIZAL
SOCIETE PHARMACEUTIQUE ALGERIENNE SOPHAL
Identification
- Active ingredient (INN)
- CEFTIZOXIME SODIQUE EXPRIME EN CEFTIZOXIME
- Internal code
- 13 B 463
- Country of Origin
- Algeria
- Pharmaceutical form
- Powder for IV/IM Injectable Sol.
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/50 flacon
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
A semisynthetic cephalosporin antibiotic which can be administered Intravenous or by suppository.
The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms.
It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.
Indications
Cetizoxime was previously indicated for the treatment of infections due to susceptible strains of bacteria.
Pharmacodynamics
Ceftizoxime is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms.
It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.
Mechanism of Action
Penicillin-binding protein 1A (Escherichia coli (strain K12)) Inhibitor Penicillin-binding protein 1B (Escherichia coli (strain K12)) Inhibitor.
Volume of Distribution
The mean apparent volume of distribution ranges between 15-28 L.
Metabolism
Ceftizoxime is not metabolized and is excreted virtually unchanged by the kidneys in 24 hours.
Route of Elimination
Excreted virtually unchanged by the kidneys in 24 hours.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.